Wellesley Pharmaceuticals looks to raise $10 million for next round of clinical trials
Wellesley Pharmaceuticals CEO David Dill tells Proactive Investors the privately held company is aiming to treat the frequent need to urinate at night with its drug Nocturol.
Dill says after the company received "compelling" data from its Phase 2 trials, it's hopeful to sign a licensing agreement with a big pharma to take over its drug. In the meantime, the company is raising capital to fund its next round of trials.
Quick facts: Wellesley Pharmaceuticals LLC